AVEO Pharmaceuticals Inc

+0.13 (+3.42%)
Products, Strategic Combinations, Regulatory

NiKang Therapeutics And Aveo Oncology Announce A Clinical Trial Collaboration And Supply Agreement To Evaluate The Combination Of Nkt2152, A Hif2α Inhibitor, And Fotivda® (Tivozanib) For The Tre

Published: 01/05/2022 19:06 GMT
AVEO Pharmaceuticals Inc (AVEO) - Nikang Therapeutics and Aveo Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of Nkt2152, a Hif2Α Inhibitor, and Fotivda® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Aveo Oncology - Nikang Will Sponsor Trial and Aveo Will Co- Fund Trial.
Aveo Oncology - Both Co & Nikang Will Provide Respective Drugs at No Cost.
Aveo Oncology - Co & Nikang Will Form a Joint Development Committee to Oversee This Collaboration.